AAN: American Academy of Neurology

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 American Academy of Neurology annual meeting.

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (AChR+ gMG), explained MINT principal investigator Richard Nowak, MD, MS, Yale School of Medicine.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, says that since sleep disorders are common, it’s important to consider that sleep can be a separate symptom from epilepsy.

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about how factors such as the sedative effects of anti-epileptic medications can mask sleep issues and diagnoses in people with epilepsy.

Jessica Robinson-Papp, MD, MS, professor of neurology at the Icahn School of Medicine at Mount Sinai, talks about the strides made in antiretroviral therapy for HIV and how these improvements lead to better patient outcomes.

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, says that sleep apnea is more common in men until after women experience menopause.

Milena Pavlova, MD, neurologist, and medical director of the Sleep Testing Center at Brigham and Women’s Faulkner Hospital, highlights how even mild cases of sleep apnea can increase the number of seizures a patient with epilepsy experiences and harm organs.

Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mt. Sinai, talks about what factors can contribute to medication nonadherence in people with HIV, and the different levels of support that might be available to patients.

David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, discusses the importance of patient safety in a first-in-human trial of NRTX-1001 GABAergic interneuron cell therapy for focal epilepsy.

David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about the first-in-human trial of interneuron cell therapy for treatment of focal epilepsy and explains the next steps.

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about the importance of treating underlying sleep disorders in patients with seizures, especially within a value-based care (VBC) model.

David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about how an emerging epilepsy treatment could transform the current level of care for patients with the condition.

The potential ethical implications for goals of care discussions between surrogate decision makers and health care providers concerning patients who reside in a state of cognitive motor dissociation were investigated in this new study from a team at Columbia University and New York Presbyterian Hospital.

Much more work needs to be done surrounding multiple sclerosis (MS) and treating pregnant patients safely, noted Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic.

Milena Pavlova, MD, neurologist and medical director of the sleep testing center at Brigham and Women’s Faulkner Hospital, discusses the profound effect obstructive sleep apnea has on epilepsy as well as cognition.

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.

Shruti Agnihotri, MD, associate professor at the University of Alabama Birmingham, discusses how value-based care can help patients who experience neurologic chronic disease states after COVID-19, in addition to patients with conditions like stroke and dementia.

Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist, talks about how data on the LGBTQ+ community in the neurology space is needed in order to provide effective value-based health care.

Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

There are limited data on potential disparities in dementia medication use in the outpatient setting, with study authors highlighting that the benefits of these medications are not equitably distributed along racial and ethnic lines because of usage differences.

A study from investigators in the Quantitative Health Science, Neurology, and Radiology departments of Mayo Clinic investigated if and how social and structural determinants of health (SSDOH) might influence mild cognitive impairment and/or risk of dementia among participants of the Mayo Clinic Study of Aging.

Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mount Sinai, discusses how neurologic symptoms in individuals with HIV can present in various places in the body while also possibly pointing to a neurologic condition.

Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist, discusses how many unknowns prevail in data concerning neurologic care for LGBTQ+ individuals.

Terminology and concepts relevant to the care of transgender and gender-diverse individuals and best practices for optimizing neurologic care in this patient population were covered in the session “Neurologic Conditions in Transgender Patients” on Sunday, April 23, at the American Academy of Neurology annual meeting.

Natalia Rost, MD, MPH, FAAN, FAHA, chief of the stroke division at Massachusetts General Hospital and chair of the American Academy of Neurology (AAN) Science Committee, previews the annual meeting and provides a glimpse into what the conference has to offer and its legacy of 75 years.

David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, previews the American Academy of Neurology (AAN) annual meeting for 2023 and says that attendees can expect not only to learn but also to leave feeling humbled and inspired.

The annual meeting of the American Academy of Neurology (AAN) will take place April 22-27 in Boston, presenting in a hybrid format a schedule packed with continuing medical education sessions, poster presentations, and cutting-edge science.